Skip to main content Accessibility help
×
Home
  • Print publication year: 2016
  • Online publication date: September 2016

13 - Pathological considerations in lung malignancy

from Section IV - Malignant conditions of the lung

Summary

Introduction

The great majority of primary malignant lung tumours are carcinomas derived predominantly from the epithelium of bronchi, bronchioles and alveoli. These neoplasms are divided, mainly on the basis of histopathological features, into four cell types: small cell carcinoma, squamous cell carcinoma, adenocarcinoma and large cell carcinoma; the latter three cell types grouped together represent non-small cell carcinomas. In recent years, it has become increasingly important to subclassify non-small cell carcinomas even in small biopsy specimens in view of therapeutic advances and the development of targeted therapies, such as tyrosine kinase inhibitors for tumours with EGFR mutations or EML4-ALK translocations, mainly seen in adenocarcinomas. Some chemotherapeutic agents, such as pemetrexed, for example, are also more efficacious in adenocarcinomas.

Small cell carcinoma is an aggressive neuroendocrine tumour, often presenting at an advanced stage. Neuroendocrine tumours of the lung are a distinct subset of tumours which share morphological, ultrastructural and immunohistochemical characteristics. In addition to small cell carcinoma, the other morphologically identifiable neuroendocrine tumours of the lung are large cell neuroendocrine carcinomas and typical and atypical carcinoid tumours.

It should be noted that lung carcinomas may be mixed and composed of more than one cell type. Sarcomatoid carcinomas comprise approximately 0.3% of lung malignancies, and this group of poorly differentiated lung carcinomas expresses a spectrum of pleomorphic, sarcomatoid and sarcomatous elements.

Rarely, malignant salivary gland type tumours, mainly adenoid cystic carcinomas or mucoepidermoid tumours, arise from the mixed seromucous glands of the trachea and bronchi, as these are similar to the minor salivary glands and can therefore give rise to the same range of tumours.

Primary malignant neurogenic, vascular and mesenchymal tumours can also occur within the lungs and the morphological features of these types of tumours reflect those seen in extrapulmonary lesions.

Whilst the lungs are often involved in disseminated nodal lymphomas of all types, primary pulmonary lymphoma is relatively rare, accounting for less than 0.5% all of primary lung neoplasms.

It should also be remembered that the lungs are a very common site for metastatic disease, most commonly due to haematogenous or lymphatic spread of extrapulmonary tumours. Dissemination within pulmonary lymphatics may be widespread, producing the appearances of so-called lymphangitis carcinomatosa.

1 Churgh, AM, Myers, JL, Tazelaar, HD, Wright, JL. Thurlbeck's Pathology of the Lung (). New York: Thieme Medical Publishers, 2005.
2 Travis, WD, Brambilla, E, Muller-Hermelink, HK, Harris, CC. Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
3 Travis, WD. Pathology of lung cancer. Clin Chest Med 32:669–92, 2011.
4 Corrin, B, Nicholson, AG. Pathology of the Lungs (). Churchill Livingstone, Elsevier, 2011.
5 Son, JW. Year-in-review of lung cancer. Tuberc Respir Dis (Seoul) 73:137–142, 2012.
6 Wen, J, Fu, JH, Zhang, W, et al. Lung carcinoma signaling pathways activated by smoking. Chin J Cancer 30:551–8, 2011.
7 Petersen, I. The morphological and molecular diagnosis of lung cancer. Dtsch Arztebl Int 108:525–31, 2011.
8 Rosai, J. Rosai and Ackerman's Surgical Pathology, Vol 1 (). Elsevier, 2011.
9 Gazdar, AF, Brambilla, E. Preneoplasia of lung cancer. Cancer Biomark 9:385–96, 2010.
10 Travis, WD, Brambilla, E, Noguchi, M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. International multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 8:381–5, 2011.
11 Modern Surgical Pathology (First Edition), 2003.
12 Yatabe, Y, Kosaka, T, Takahashi, T, et al. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 29:633–9, 2005.
13 Yoshizawa, A, Motoi, N, Riely, GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 24:653–64, 2011.
14 Kadota, K, Suzuki, K, Colovos, C, et al. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Mod Pathol 25:260–71, 2012.
15 Travis, WD, Rekhtman, N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 32:22–31, 2011.
16 Brandao, GD, Brega, EF, Spatz, A. The role of molecular pathology in non-small-cell lung carcinoma–now and in the future. Curr Oncol 19:S24-32, 2012.
17 Heist, RS, Sequist, LV, Engelman, JA. Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol 7:924–33, 2012.
18 Pirker, R, Pereira, JR, Pawel, J von, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 13:33–42, 2012.
19 Soh, J, Toyooka, S, Ichihara, S, et al. Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J Thorac Oncol 3:340–7, 2008.
20 Rodig, SJ, Mino-Kenudson, M, Dacic, S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15:5216–23, 2009.
21 Marchetti, A, Felicioni, L, Malatesta, S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 29:3574–9, 2011.
22 Weiss, J, Sos, ML, Seidel, D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2:62–93, 2010.
23 Yamamoto, H, Shigematsu, H, Nomura, M, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 68:6913–21, 2008.
24 Kawano, O, Sasaki, H, Endo, K, et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 54:209–15, 2006.
25 GJ, MJ, K, Jeon, HS, et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS and TP53 mutations in non-small cell lung cancers. Lung Cancer 69:279–83, 2010.
26 Kishimoto, Y, Murakami, Y, Shiraishi, M, et al. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res 52:4799–4804, 1992.
27 Mandinova, A, Lee, SW. The p53 pathway as a target in cancer therapeutics: obstacles and promise. Sci Transl Med 3:64–61, 2011.
28 Hammerman, PS, Sos, ML, Ramos, AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1:78–89, 2011.
29 Gustafsson, BI, Kidd, M, Chan, A, et al. Bronchopulmonary neuroendocrine tumors. Cancer 113:5–21, 2008.
30 Travis, WD. Advances in neuroendocrine lung tumors. Ann Oncol 21 (Suppl 7): vii, 65–71, 2010.
31 Tsuta, K, Raso, MG, Kalhor, N, et al. Histologic features of low- and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung. Lung Cancer 71:34–41, 2011.
32 Bertino, EM, Confer, PD, Colonna, JE, et al. Pulmonary neuroendocrine/carcinoid tumors: a review article. Cancer 115:4434–41, 2009.
33 Carretta, A, Libretti, L, Taccagni, G, et al. Salivary gland-type mixed tumor (pleomorphic adenoma) of the lung. Interact Cardiovasc Thorac Surg 3:663–5, 2004.
34 Kitada, M, Ozawa, K, Sato, K, et al. Adenoid cystic carcinoma of the peripheral lung: a case report. World J Surg Oncol 8:74, 2010.
35 Cortés-Télles, A, Mendoza-Posada, D. Primary adenoid cystic carcinoma of the tracheobronchial tree: a decade-long experience at a health centre in Mexico. Lung India 29:325–8, 2012.
36 Macarenco, RS, Uphoff, TS, Gilmer, HF, et al. Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Mod Pathol 21:1168–75, 2008.
37 Kitada, M, Matsuda, Y, Sato, K, et al. Mucoepidermoid carcinoma of the lung: a case report. J Cardiothorac Surg 6:132, 2011.
38 Graham, BB, Mathisen, DJ, Mark, EJ, et al. Primary pulmonary lymphoma. Ann Thorac Surg 80:1248–53, 2005.
39 Cadranel, J, Wislez, M, Antoine, M. Primary pulmonary lymphoma. Eur Respir J 20:750–62, 2002.
40 Ferraro, P, Trastek, VF, Adlakha, H, et al. Primary non-Hodgkin's lymphoma of the lung. Ann Thorac Surg 69:993–7, 2000.
41 Parissis, H. Forty years literature review of primary lung lymphoma. J Cardiothorac Surg 6:23, 2011.